98%
921
2 minutes
20
Background And Purpose: In real-world practice, the benefit of mechanical thrombectomy (MT) is uncertain in stroke patients with very favorable or poor prognostic profiles at baseline. We studied the effectiveness of MT versus medical treatment stratifying by different baseline prognostic factors.
Methods: Retrospective analysis of 2,588 patients with an ischemic stroke due to large vessel occlusion nested in the population-based registry of stroke code activations in Catalonia from January 2017 to June 2019. The effect of MT on good functional outcome (modified Rankin Score ≤2) and survival at 3 months was studied using inverse probability of treatment weighting (IPTW) analysis in three pre-defined baseline prognostic groups: poor (if pre-stroke disability, age >85 years, National Institutes of Health Stroke Scale [NIHSS] >25, time from onset >6 hours, Alberta Stroke Program Early CT Score <6, proximal vertebrobasilar occlusion, supratherapeutic international normalized ratio >3), good (if NIHSS <6 or distal occlusion, in the absence of poor prognostic factors), or reference (not meeting other groups' criteria).
Results: Patients receiving MT (n=1,996, 77%) were younger, had less pre-stroke disability, and received systemic thrombolysis less frequently. These differences were balanced after the IPTW stratified by prognosis. MT was associated with good functional outcome in the reference (odds ratio [OR], 2.9; 95% confidence interval [CI], 2.0 to 4.4), and especially in the poor baseline prognostic stratum (OR, 3.9; 95% CI, 2.6 to 5.9), but not in the good prognostic stratum. MT was associated with survival only in the poor prognostic stratum (OR, 2.6; 95% CI, 2.0 to 3.3).
Conclusions: Despite their worse overall outcomes, the impact of thrombectomy over medical management was more substantial in patients with poorer baseline prognostic factors than patients with good prognostic factors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521260 | PMC |
http://dx.doi.org/10.5853/jos.2021.00962 | DOI Listing |
J Nephrol
September 2025
Institute of Nephrology, Madras Medical College, Chennai, India.
Background: IgA nephropathy is a disease with a highly variable natural history, for which there is an increasing understanding of the role of complement activation in its pathogenesis and progression. We aimed to assess the clinical and prognostic implications of C4d staining in the kidney biopsy of IgA nephropathy patients.
Methods: This was a retrospective observational study wherein the medical records of IgA nephropathy patients were reviewed and baseline characteristics, kidney biopsy findings, treatment response and follow-up data were noted.
J Neurooncol
September 2025
Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Purpose: Frailty measures are critical for predicting outcomes in metastatic spine disease (MSD) patients. This study aimed to evaluate frailty measures throughout the disease process.
Methods: This retrospective analysis measured frailty in MSD patients at multiple time points using a modified Metastatic Spinal Tumor Frailty Index (MSTFI).
J Neurooncol
September 2025
Department of Brain and Neurosciences, Division of Neurosurgery, Faculty of Medicine, Tottori University, Tottori, Japan.
Introduction: Hypertension, the most common adverse events associated with bevacizumab (BEV) treatment, has been proposed as a potential biomarker of treatment response in glioblastoma (GBM) patients. This study aimed to evaluate whether the timing of hypertension serves as a prognostic value in GBM patients.
Methods: This retrospective study consisting of 56 GBM patients treated with initial BEV between 2013 and 2024.
Wien Klin Wochenschr
September 2025
3rd Medical Department with Cardiology and Intensive Care Medicine, Clinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.
Background: Acute heart failure (AHF) significantly contributes to cardiovascular morbidity and mortality, bearing a substantial socioeconomic burden. While the dynamics of chronic heart failure have been extensively explored in global patient cohorts, comprehensive data specific to AHF remain limited.
Methods: This retrospective, single-center, real-world study comprises hospitalized patients with AHF, admitted to a tertiary care hospital in Vienna, Austria, between 1 January 2012 and 31 December 2019.
Pediatr Nephrol
September 2025
Pediatric Nephrology Department, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain.
Copeptin, a stable glycopeptide derived from the precursor of arginine vasopressin (AVP), has emerged as a valuable surrogate biomarker for AVP due to its stability and ease of measurement. This narrative review explores the physiological role of copeptin, its utility as a diagnostic and prognostic biomarker in different kidney diseases, and its clinical relevance in renal tubular disorders. The clinical application of copeptin as a diagnostic biomarker is best established in the differential diagnosis of polyuria-polydipsia syndrome (PPS), distinguishing nephrogenic diabetes insipidus (NDI) from central diabetes insipidus (CDI) and primary polydipsia (PP).
View Article and Find Full Text PDF